{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"scPharmaceuticals Inc."},"Symbol":{"label":"Symbol","value":"SCPH"},"Address":{"label":"Address","value":"2400 DISTRICT AVENUE,SUITE 310, BURLINGTON, Massachusetts, 01803, United States"},"Phone":{"label":"Phone","value":"+1 617 517-0730"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"scPharmaceuticals Inc is a pharmaceutical company. Its pipeline includes products in various stages of clinical and non-clinical development. It focuses on pharmaceutical products in the cardiovascular and infectious disease therapeutic areas. The company's lead product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure."},"CompanyUrl":{"label":"Company Url","value":"https://www.scpharmaceuticals.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"John H. Tucker","title":"President, Chief Executive Officer & Director"},{"name":"John Mohr","title":"Senior VP-Clinical Development & Medical Affairs"},{"name":"Mike Hassman","title":"Senior Vice President-Technical Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}